web analytics

di Giancarlo Nicoli

A couple of rumors yesterday regarding Dendreon Corporation (DNDN).

Shares surged, on more than tripled average turnover, almost 17% reportedly after U.S. health regulators published a critical review of rival Amgen Inc.’s (AMGN) drug for prostate cancer. Where’s the connection between FDA review of Amgen’s drug and Dendreon is puzzling me.


Rumor #1: January turnover much bigger than expected.

Rumor #2: Amgen is going to buy DNDN out. With an offer in the $21 range.

These are rumors, not news, there are no PRs and no confirmations anywhere.
Take these rumors with plenty of salt.


Comments are closed.

%d bloggers like this: